ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)
ARS Pharmaceuticals' (SPRY) quarterly Finished Goods came in at $7.3 million in Q1 2025, up 39.49% quarter-over-quarter from $5.2 million in Q4 2024.
ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025) Analysis & Trends
ARS Pharmaceuticals has disclosed Finished Goods across 2 years of filings, most recently posting $7.3 million for Q1 2025.
- Finished Goods for Q1 2025 came in at $7.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $7.3 million (changed N/A YoY), and the FY2024 annual result was $5.2 million, changed N/A from the prior year.
- Finished Goods came in at $7.3 million for Q1 2025 at ARS Pharmaceuticals, up from $5.2 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $7.3 million in Q1 2025 to a low of $5.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | ARS Pharmaceuticals | 954.24 Mn | 753.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 7.27 Mn |
| Dec 31, 2024 | 5.21 Mn |